CliffBio
small molecule

IBANDRONATE SODIUM

IBANDRONATE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameIBANDRONATE SODIUM
Active ingredientIBANDRONATE SODIUM
StrengthEQ 150MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2012
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.